To validate the clinical relevance of this study, we compared the expression of Mig-6 in lung adenocarcinoma specimens obtained from patients both before treatment with EGFR-TKIs and after the development of acquired EGFR-TKI resistance. The gene discussed is ERRFI1; the disease is lung adenocarcinoma.